Targeted drug delivery to tumors: myths, reality and possibility.
Targeted drug delivery to tumors: myths, reality and possibility.
复制标题
DOI：
10.1016/j.jconrel.2011.06.001
复制
发表时间：
2011-08-10
期刊：
影响因子：
--
通讯作者：
Park K
中科院分区：
文献类型：
--
作者：
Bae YH;Park K
药物输送研究的最终目标是通过开发临床上有用的制剂来帮助患者。在过去的几十年中，受控药物递送技术取得了显着进步，导致各种临床制剂的开发，提高了患者的依从性和便利性[1]。目前的技术允许以期望的释放动力学递送药物达数天至数年的延长时间段。口服和透皮给药系统常规地递送药物24小时，大大提高了药物疗效并最大限度地减少了副作用。可植入系统可以在局部输送药物数月，甚至数年。虽然已经取得了重大进展，但仍有一些领域需要进行实质性改进，以达到下一个临床相关性水平。一个这样的领域是向实体肿瘤靶向药物递送。靶向药物递送的临床显著影响在于特异性靶向药物或药物载体以最小化药物源性全身毒性作用的能力。潜在的癌症和基因疗法的成功翻译（从实验室到床边），特别是小干扰RNA（siRNA）递送，将在很大程度上取决于靶向药物递送策略。克服识别成功的靶向药物递送策略的许多挑战需要理解涉及静脉内（iv）施用后药物或药物载体向靶位点的运输的事件以及与特定靶疾病和身体对药物递送系统的反应相关的问题。目前对药物输送领域所面临的问题缺乏明确的认识，可以预期，在未来几年中，靶向药物输送技术只会取得微不足道的进展。亚历山大T.佛罗伦萨是少数几个提高人们对基于纳米颗粒的药物靶向的夸大声明的认识的人之一[2，3]。需要更好地理解和理解它们，以便在靶向肿瘤的药物方面取得更大的成功。因此，解决可能影响改进的靶向药物递送系统的发展的各种问题和因素将是有益的。许多术语已用于描述纳米尺寸的药物递送系统，并且在此术语“纳米颗粒”用于表示一系列系统，包括纳米载体、纳米载体、纳米系统、纳米结构和文献中使用的其他术语。
The ultimate goal of drug delivery research is to help patients by developing clinically useful formulations. During the last several decades controlled drug delivery technology has advanced significantly, leading to the development of various clinical formulations improving patient compliance and convenience [1]. Current technologies allow delivery of drugs at desired release kinetics for extended periods of time ranging from days to years. Oral and transdermal drug delivery systems routinely deliver drugs for 24h, substantially improving drug efficacy and minimizing side effects. Implantable systems can locally deliver drugs for months, even years. While significant advances have been made, there are still areas where substantial improvements need to be made to reach the next level of clinical relevance. One such area is targeted drug delivery to solid tumors. The clinically significant impact of targeted drug delivery lies in the ability to specifically target a drug or drug carrier to minimize drug-originated systemic toxic effects. Successful translation (from bench to bedside) of potential cancer and gene therapies, particularly small interfering RNA (siRNA) delivery, will largely depend on targeted drug delivery strategies. Overcoming the many challenges of identifying a successful targeted drug delivery strategy requires an understanding of events involving transport of drug or drug carrier to a target site after intravenous (iv) administration as well as issues relevant for specific target diseases and the body's response toward a drug delivery system. The current lack of clear recognition of problems facing the drug delivery field can be anticipated to result in only marginal advances in targeted drug delivery technologies in the coming years. The current unmet needs and challenges in this area were summarized by Professor Alexander T. Florence who is one of the few who raised awareness on the exaggerated claims of the nanoparticle-based drug targeting [2, 3]. They need to be better appreciated and understood for achieving greater success in drug targeting to tumors. Thus, it would be profitable to address a variety of issues and factors that could affect the development of improved targeted drug delivery systems. Many terms have been used to describe nano-sized drug delivery systems, and here the term “nanoparticle” is used to represent a spectrum of systems, including nanocarrier, nanovehicle, nanosystem, nanostructure, and other terms used in the literature.
登录
查看更多内容
影响因子：
11.2
作者：
Charafe-Jauffret E;Ginestier C;Iovino F;Wicinski J;Cervera N;Finetti P;Hur MH;Diebel ME;Monville F;Dutcher J;Brown M;Viens P;Xerri L;Bertucci F;Stassi G;Dontu G;Birnbaum D;Wicha MS
通讯作者：
Wicha MS
影响因子：
10.8
作者：
Canal, Fabiana;Vicent, Maria J.;Schiavon, Oddone
通讯作者：
Schiavon, Oddone
影响因子：
29.4
作者：
Barbé, C;Bartlett, J;Calleja, G
通讯作者：
Calleja, G
影响因子：
64.5
作者：
Gupta PB;Onder TT;Jiang G;Tao K;Kuperwasser C;Weinberg RA;Lander ES
通讯作者：
Lander ES
影响因子：
5.8
作者：
Burt, HM;Zhang, XC;Hunter, WL
通讯作者：
Hunter, WL